RTRX Retrophin, Inc.

18.84
+0  (2%)
Previous Close 18.39
Open 18.43
Price To book 2.27
Market Cap 717.67M
Shares 38,093,000
Volume 187,589
Short Ratio 11.48
Av. Daily Volume 411,179

SEC filingsSee all SEC filings

  1. DEF 14A - Other definitive proxy statements 17761637
  2. 8-K - Current report 17761534
  3. 8-K - Current report 17716109
  4. 8-K - Current report 17675952
  5. 10-K - Annual report (Section 13 and 15(d), not S-K Item 405) 17655312

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 dosing to commence mid-2017.
RE-024
Pantothenate kinase-associated neurodegeneration (PKAN)
NDA filing due 2017
Liquid ursodeoxycholic acid (L-UDCA)
Primary biliary cholangitis (PBC)
Approved Mar 18 2015
Cholbam
Rare Bile Acid Synthesis Disorders
Phase 3 trial to be initiated 2H 2017.
Sparsentan
Focal segmental glomerulosclerosis (FSGS)